ML604440

ML604440 is a specific and cell-permeable Proteasome β1i ( LMP2 ) subunit inhibitor. ML604440 can be used in experimental colitis, EAE and autoimmune disease research. ML604440 shows synergistic effects and advantageous when combined with LMP7 inhibitor In Vitro ML604440 (300 nM; overnight) treatment shows no influence on the surface expression of H-2K b in wt or LMP7-deficient mice splenocytes. ML604440 (300 nM; 24 h) treatment shows no significant inhibition of IL-6 secretion by mouse splenocytes or human PBMCs. ML604440 (300 nM; 3 d) shows no influence on the percentage of IL-17A-producing CD4 + T cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ML604440 (intraperitoneal injection; 10 mg/kg; once daily; 7 d) treatment inhibits LMP2 in vivo, shows no significant changes in platelet counts. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6J mice (6-8-wks old) injected with anti-platelet monoclonal antibodyDosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg; once daily; 7 days Result: Inhibited LMP2 in vivo. Showed no significant improvement in platelet counts in mice immunized by monoclonal rat anti-mouse CD41 platelet antibody. Form:Solid IC50& Target:proteasome β1i (LMP2) subunit inhibitor

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet